EP Patent

EP2124916A1 — Use of histone deacetylase inhibitors for the treatment of central nervous system metastases

Assigned to US Department of Health and Human Services · Expires 2009-12-02 · 16y expired

What this patent protects

Disclosed is a method of treating a localized carcinoma central nervous system (CNS) metastasis of extra-CNS origin, the method comprising systemically administering an effective amount of a histone deacetylase (HDAC) inhibitor (HDI) to a subject in need of treatment for the loca…

USPTO Abstract

Disclosed is a method of treating a localized carcinoma central nervous system (CNS) metastasis of extra-CNS origin, the method comprising systemically administering an effective amount of a histone deacetylase (HDAC) inhibitor (HDI) to a subject in need of treatment for the localized carcinoma CNS metastasis of extra-CNS origin. The HDI can be any HDI capable of crossing the blood-brain barrier (BBB) such as vorinostat. The localized carcinoma CNS metastasis of extra-CNS origin can be a localized carcinoma brain metastasis. The localized carcinoma brain metastasis can originate in the breast. The CNS metastasis treated can be a micrometastasis, a brain tumor, or an intervening stage of brain cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP2124916A1
Jurisdiction
EP
Classification
—
Expires
2009-12-02
Drug substance claim
No
Drug product claim
No
Assignee
US Department of Health and Human Services
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.